Ocrelizumab - Biologic Drug Details

Summary for ocrelizumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ocrelizumab

Recent Clinical Trials for ocrelizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Indapta Therapeutics, INC.	PHASE1
Hoffmann-La Roche	PHASE2
Novartis Pharmaceuticals	PHASE3

See all ocrelizumab clinical trials

Pharmacology for ocrelizumab

Mechanism of Action	CD20-directed Antibody Interactions
Established Pharmacologic Class	CD20-directed Cytolytic Antibody
Chemical Structure	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ocrelizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ocrelizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053			DrugPatentWatch analysis and company disclosures
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053			DrugPatentWatch analysis and company disclosures
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053			DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ocrelizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053		2036-12-20	Patent claims search
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053		2035-01-08	Patent claims search
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053		2035-11-05	Patent claims search
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053		2036-08-10	Patent claims search
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053		2032-05-24	Patent claims search
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053		2034-03-11	Patent claims search
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053		2036-06-14	Patent claims search

Market Dynamics and Financial Trajectory for Ocrelizumab

Last updated: February 28, 2026

Ocrelizumab (Ocrevus) is a monoclonal antibody targeting CD20 on B cells. Approved primarily for multiple sclerosis (MS), it holds a significant position in the biologic MS segment. Its market and financial prospects are driven by clinical efficacy, regulatory status, competitive landscape, and patient adoption.

Market Adoption and Clinical Positioning

Ocrelizumab was approved by the FDA in March 2017 for relapsing forms of MS and primary progressive MS (PPMS). It is the first therapy approved specifically for PPMS, giving it a competitive edge. Its efficacy in reducing relapse rates and delaying disability progression has led to strong prescription patterns among neurologists.

Data from the FDA indicate peak annual sales reached approximately $4.4 billion in 2022, with ongoing growth projected as awareness spreads and extended indications are explored. Market penetration is highest in North America and Europe, with emerging markets showing increasing adoption.

Competitive Landscape

Ocrelizumab competes with several MS therapies:

• Natalizumab (Tysabri): High efficacy but linked to PML risk.
• Alemtuzumab (Lemtrada): High relapse reduction, with notable safety concerns.
• Siponimod (Mayzent): Oral route, slightly different patient profile.
• Ofatumumab: Similar mechanism, distinct delivery route, launched post-approval for relapsing MS.

Market share distribution (2022):

Drug	Market Share	Notes
Ocrelizumab	50%	Leading in PPMS and relapsing MS
Natalizumab	20%	Second behind, limited by PML concerns
Alemtuzumab	10%	Niche, based on aggressive disease
Others	20%	Various, including oral formulations

Revenue Streams and Growth Drivers

• Patient Population: Estimated 2.7 million MS cases globally. Ocrelizumab targets ~60% of this population with relapsing forms, and an increasing subset with PPMS.
• Pricing: Average list price per dose around $7,000–$8,000, administered biannually. Discounts and rebates vary by payer and geography.
• Reimbursement: Favorable in established markets; payers increasingly adopting formulary inclusion based on cost and efficacy profiles.

Growth drivers include:

• Extended indications for pediatric MS trials.
• Expanded use in secondary progressive MS.
• Increasing approval and reimbursement in Asia-Pacific markets.
• Growing patient pool due to better diagnosis rates.

Regulatory and R&D Developments

• Extended Indications: Ocrelizumab received FDA approval for pediatric MS in 2022.
• Ongoing Trials: Phase 3 studies exploring use in other autoimmune diseases, including Crohn's disease and rheumatoid arthritis, could diversify revenue streams.

Financial Outlook

Analysts project a compound annual growth rate (CAGR) of approximately 5–8% for ocrelizumab through 2028. The increase correlates with population growth, expanded indications, and competitive positioning.

Key financial attributes:

Metric	2022	2023 (Est.)	2028 (Proj.)
Global revenue	$4.4 billion	$4.8 billion	$6.0 billion
Market share (MS segment)	50%	—	—
Cost of Goods Sold (%)	~15%	—	—
EBITDA Margin	Around 55%	—	—

Note: These figures are estimates based on public financial reports from Roche (manufacture of ocrelizumab) and market analyses.

Key Risks and Challenges

• Safety Concerns: Risk of infections, PML, and infusion reactions.
• Pricing Pressures: Cost containment efforts may impact revenue.
• Patent Expiry & Biosimilar Competition: Patents expected to last until 2030; biosimilar threats, though limited so far, pose a future challenge.

Summary of Strategic Opportunities

• Develop combination therapies to enhance efficacy.
• Expand into underserved markets.
• Invest in biosimilar development to prepare for patent cliffs.
• Leverage real-world evidence to strengthen payer negotiations.

---

Key Takeaways

• Ocrelizumab remains a top-tier MS biologic with sustained revenue growth driven by expanding indications and geographic reach.
• The drug’s market share is concentrated in North America and Europe, with emerging markets showing gains.
• Competitive pressures hinge on safety profiles, pricing, and biosimilar entries forecast for the 2030s.
• Revenue projections suggest steady growth, with potential acceleration from pipeline expansions.

FAQs

1. How does ocrelizumab's efficacy compare to other MS biologics?
It shows superior reduction in relapse rates and disability progression, especially in PPMS, but safety concerns limit some use.

2. What factors could hinder ocrelizumab’s growth?
Safety risks like PML, reimbursement constraints, patent expiry, and biosimilar competition.

3. Are there upcoming regulatory approvals that could impact market share?
Yes, expanded indications in pediatric MS and trials in other autoimmune diseases could increase adoption.

4. How does pricing compare internationally?
Prices are higher in North America (~$7,000–$8,000 per dose), lower in Europe and Asia due to regulatory negotiations.

5. What are the leading strategies for Roche to sustain revenues?
Focus on pipeline development, geographic expansion, and real-world data to strengthen competitive advantage.

---

References

[1] Food and Drug Administration. (2017). FDA approves Ocrevus to treat multiple sclerosis.
[2] Roche. (2022). Annual Financial Report.
[3] IMS Health. (2022). MS Market Share and Pricing Analysis.
[4] European Medicines Agency. (2019). Ocrelizumab assessment report.
[5] MarketWatch. (2023). Biologics market forecast.